Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Curasan AG    CURK   DE000A2YPGM4

CURASAN AG

(CURK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

curasan : postpones publication of FY results 2019

04/15/2020 | 04:56am EST

Kleinostheim, April 15, 2020 - The Management of curasan AG, Germany, (shares: ISIN DE000A2YPGM4 and DE000A2YPGQ5; convertible bond: ISIN DE000A2TR497) announces that the publication of its full year financial results 2019 originally scheduled for April 29, 2020, is postponed indefinitely.

Same applies to the General Annual Meeting planned for June 25, 2020.

On 24 February, 2020, curasan AG had applied for povisional insolvency proceedings at the Aschaffenburg District Court due to overindebtedness of the company.

Contact curasan AG:
Andrea Weidner
Investor Relations &
Corporate Communications
+49 6027 40 900-51
ir@curasan.com

About curasan AG:

curasan develops, manufactures and markets biomaterials and medical devices in the field of bone and tissue regeneration, wound healing and osteoarthritis therapy. As a pioneer and global technology leader in the growing field of regenerative medicine, curasan is specialized primarily on biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic and spinal applications, i.e. materials mimicking biological structures. Numerous patents and a broad record of scientific publications demonstrate the clinical success of the products and the highly innovative strength of curasan. Dental and orthopaedic clinicians worldwide benefit from the broad range of the premium quality and easy to use portfolio offered by the technology leader curasan. curasan maintains its own high-tech facilities for research, development and manufacturing of biomaterials in Frankfurt/Main, Germany. In addition to its headquarters, the company has a subsidiary, curasan, Inc., in Wake Forest, near Raleigh, N.C., USA. curasan´s innovative products are cleared by the US Food and Drug Administration (FDA) and many other international authorities and available in almost 50 countries worldwide. curasan AG is a public company listed in the General Standard at the Frankfurt Stock Exchange.

Disclaimer

curasan AG published this content on 15 April 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 April 2020 08:55:01 UTC


© Publicnow 2020
All news about CURASAN AG
07/29CURASAN AG : Preliminary announcement of the publication of financial reports ac..
EQ
06/30CURASAN AG : curasan AG postpones annual financial report 2019 to 31 July 2020
EQ
06/29CURASAN AG : Preliminary announcement of the publication of financial reports ac..
EQ
06/25CURASAN AG : curasan AG and Donau Invest, Vienna, agree on a restructuring conce..
EQ
06/17CURASAN AG : Notification of a loss amounting to half of the equity capital in a..
EQ
06/08CURASAN AG : Release according to Article 40, Section 1 of the WpHG [the German ..
EQ
06/03CURASAN AG : Opening of insolvency proceedings on the assets of curasan AG
EQ
05/25CURASAN AG : EBITDA 2019 probably better than results forecast
EQ
04/28CURASAN AG : Preliminary announcement of the publication of financial reports ac..
EQ
04/15CURASAN : postpones publication of FY results 2019
PU
More news
Financials
Sales 2019 6,20 M 7,38 M 7,38 M
Net income 2019 -4,68 M -5,57 M -5,57 M
Net Debt 2019 1,19 M 1,42 M 1,42 M
P/E ratio 2019 -1,84x
Yield 2019 -
Capitalization 1,18 M 1,40 M 1,40 M
EV / Sales 2018 1,59x
EV / Sales 2019 1,58x
Nbr of Employees -
Free-Float -
Chart CURASAN AG
Duration : Period :
curasan AG Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 0,13 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Torben Sorensen Chief Executive Officer
Detlef Wilke Chairman-Supervisory Board
Fabian Peters Technical Director
Christine Böhm Chief Medical Officer
Isabella de Krassny Member-Supervisory Board